Archief

Hormonaal monotherapie

12 april 2021

Inclusie Hormoonreceptor positief, M+ mammacarcinoom. Kan tegelijk met radiotherapie. To do voor start Evaluatie met menopauzale status (kliniek, biochemie). Premenopauzaal: oestradiol ≥0,03 nmol/L en LH ≤14 U/L of…

Eexemestaan + everolimus

Algemeen Inclusie Hormoonreceptor positief, HER2 negatief, M+ of locally advanced mammacarcinoom (≥ 2e lijns hormonale behandeling) Tumor moet ooit progressief geweest zijn op een aromatase remmer, of recidief…

AI/fulvestrant + CDK4/6 remmer

Inclusie Hormoonreceptor positief, HER2 negatief, M+ of locally advanced mammacarcinoom (alle lijnen, als eerder nog geen CDK remmer is gegeven) In combinatie met niet-steroïdale aromatase remmer (alle lijnen)…

PD-L1 Imaging

ImmunoPET imaging with 89Zr-MPDL3280A in patients with locally advanced or metastatic non-small cell lung cancer, bladder cancer or triple-negative breast cancer prior to MPDL3280A treatment. Protocolnummer: MPDL3280A-img-04205 EudraCT…

PD-L1 treatment

MPDL3280A treatment in patients with locally advanced or metastatic non-small cell lung, bladder and triple negative breast cancer after investigational imaging. Protocolnummer: ML29755 EudraCT nummer: 2015-000907-19 METc nummer:…

MK3475-355

A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer –…

FUTURE

Functional selection of advanced breast cancer patients for Talazoparib treatment using the repair capacity (RECAP) test: The FUTURE trial Eudract nummer: 2018-002914-10 METc nummer: 2020/316 Samenvatting Deze studie…

ZEPHIR

A phase II prospective imaging study evaluating the utility of pre-treatment zirconium-89 labelled trastuzumab PET/CT and an early FDG-PET/CT response to identify patients with advanced HER-2 positive breast…

TULIP

A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician’s choice in patients with HER2-positive unresectable locally advanced or metastatic…

SONImage

Samenvatting Deze studie is een zijstudie van de SONIA studie en is binnen deze studie één van de studies waarin biomarkers worden onderzocht. Biomarkers zijn biologische kenmerken die…

ImaGelato

Can 89Zr-atezolizumab PET scan identify patients with metastatic invasive lobular breast cancer who will respond to chemotherapy-immune checkpoint inhibition? ImaGelato Protocolnummer: 201900180 Eudractnummer: 2019-001197-28 METc nummer: 2019/232 Onderzoekscode:…

G1T48

Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women with Estrogen Receptor-Positive, HER2-Negative Advanced Breast…

SONIA

Endocrine therapy plus CDK 4/6 inhibition in first or second line for hormone receptor positive advanced breast cancer. SONIA. Eudract nummer: 2017-002334-23 METc nummer: 2018/351 Samenvatting Het belangrijkste…

GDC-0810

An open-label, phase I/IIA study of GDC-0810 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer (GO29642) SERD Genentech Protocolnummer: GO29642 Eudract nummer: 2014-004852-77…